Category: Research
Penn Medicine’s Sarcoidosis App Now on Android!
We received a great deal of feedback asking when the app would be available on android devices. It has always been our goal to have the app available to everyone to give equal access to these sarcoidosis resources, as well as to help sarcoidosis researchers obtain the...
Sarcoidosis Treatment and Outcomes: What is Most Important to You?
As an organization dedicated to optimizing patient outcomes from treatments for sarcoidosis, FSR is always looking for ways to help ensure that the patient voice is represented in research and projects relating to sarcoidosis. As part of these efforts, we are sharing...
Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study
Disclaimer: This approach to treatment is still under active investigation to confirm it is safe for patients and effective when used in conjunction with other approved therapies. We strongly discourage use of nicotine in any form, including tobacco smoking, smokeless...
PRESS RELEASE: OPIOID EPIDEMIC Impacts Patients suffering from Orphan Disease of Sarcoidosis
CHICAGO, IL, December 19, 2017. Effective and appropriate management of chronic pain is a nation-wide priority, especially given the current US opioid crisis. The Foundation for Sarcoidosis Research, in collaboration with the Cleveland Clinic and Araim...
A Year in Review: FSR’s Research Initiatives
This year, FSR made some huge progress on our research agenda. This coming year promises to build on that progress, with new developments on several major projects that will lead to better understanding of the disease and therapies, more interest on the part of young...
Phase 1 Trial for New ILD Therapy Begins
The following is an excerpt from a press release by aTyr Pharma, Inc detailing their new study focusing on a potential therapy for treating interstitial lung diseases: SAN DIEGO, Nov. 27, 2017 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics...
Study of ACZ885 (Canakinumab) in Patients with Pulmonary Sarcoidosis
The purpose of this study is to find out if the drug ACZ885 (Canakinumab) will improve lung function and also lower inflammation in patients with pulmonary sarcoidosis. This is a double blind study. This means neither participants nor researchers will know which...